SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Preferred Ustekinumab Products for PsA & PsO (Pharmacy)

Drug Requested: select one drug below

❑ **Stelara®** (ustekinumab) ***For VCUHS Members only**	❑ **Selarsdi™** (ustekinumab-aekn)	❑ **Yesintek™** (ustekinumab-kfce)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. **Check the diagnosis below that applies.**

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Skyrizi) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

(Continued on next page)

- Will the member be discontinuing a previously prescribed biologic if approved for requested medication?

  ❑ Yes **OR** ❑ No

- If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

  Medication to be discontinued: _____ **Effective date:** _____

  Medication to be initiated: _____ **Effective date:** _____

❑ Diagnosis: Active Psoriatic Arthritis

Dosing: SubQ: 45 mg at 0 and 4 weeks; then every 12 weeks thereafter. **NOTE:** When used for psoriatic arthritis, may be administered alone or in combination with methotrexate.

Coexistent psoriatic arthritis and moderate-to-severe plaque psoriasis in member's >100 kg: Initial and maintenance: 90 mg at 0 and 4 weeks; then every 12 weeks thereafter.

- ❑ Member is ≥ 6 years old and has a diagnosis of active **psoriatic arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member tried and failed at least **one DMARD** for at least **three (3) months** **(check each tried below):**

❑ methotrexate	❑ azathioprine	❑ hydroxychloroquine
❑ sulfasalazine	❑ leflunomide	❑ auranofin
❑ Other: _____		

❑ Diagnosis: Moderate-to-Severe Plaque Psoriasis

Dosing: SubQ: ≤100 kg: 45 mg at 0 and 4 weeks; then every 12 weeks thereafter. >100 kg: 90 mg at 0 and 4 weeks; then every 12 weeks thereafter. **NOTE:** Doses of 45 mg given to patient's >100 kg were also efficacious; however, 90 mg is the recommended dose in these patients due to greater efficacy

- ❑ Member is ≥ 6 years old and has a diagnosis of moderate-to-severe **plaque psoriasis**
- ❑ Prescribed by or in consultation with a **Dermatologist**
- ❑ Member tried and failed at least **ONE (1)** of either **Phototherapy or Alternative Systemic Therapy** for at least **three (3) months** **(check each tried below)**:

❑ **Phototherapy:** ❑ **UV Light Therapy** ❑ NB UV-B ❑ PUVA	❑ **Alternative Systemic Therapy:** ❑ **Oral Medications** ❑ acitretin ❑ methotrexate ❑ cyclosporine

(Continued on next page)

Medication being provided by a Specialty Pharmacy – Proprium Rx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee:** ~~1/21/2010; 7/22/2016;~~ **9/16/2022**
REVISED/UPDATED: ~~10/28/2014; 12/2/2014; 1/15/2015; 5/22/2015;~~ ~~12/29/2015~~; ~~7/22/2016~~; ~~8/11/2016~~; ~~9/22/2016~~; ~~12/16/2016~~; ~~1/31/2017~~; ~~7/24/2017~~; ~~9/1/2017~~; ~~10/10/2017~~; ~~12/16/2017~~; ~~3/31/2018;11/23/2018 (Reformatted) 9/18/2019; 11/20/2019~~, ~~3/31/2020;~~ ~~10/4/2022;~~ ~~12/30/2022~~~~;10/30/2023,~~ **12/31/2025**